Allworth Financial
MLTX icon

Allworth Financial’s MoonLake Immunotherapeutics MLTX Stock Holding History

Allworth Financial’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$33.4K Hold
1,714
– – ﹤0.01% 2947
2026
Q2 		$33.4K Buy
1,714
+1,045
+156% +$18.9K ﹤0.01% 2811
2026
Q1 		$12.5K Buy
669
+288
+76% +$4.77K ﹤0.01% 3353
2025
Q4 		$5.02K Buy
381
+365
+2,281% +$4.31K ﹤0.01% 3710
2025
Q3 		$115 Sell
16
-34
-68% -$1.77K ﹤0.01% 4666
2025
Q2 		$2.36K Buy
+50
New +$2.04K ﹤0.01% 3629

Other funds holding MLTX

JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Jump Financial
Jump Financial Chicago, Illinois $13.9B AUM 45.06% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Allworth Financial's MLTX Position: Q3 2026 in Review

Allworth Financial held its MoonLake Immunotherapeutics (MLTX) position steady in Q3 2026 at 1,714 shares worth $33.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2947.

Allworth Financial first reported a position in MLTX in Q2 2025 and has held it in 6 quarters since. 106 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Allworth Financial held 1,714 shares of MoonLake Immunotherapeutics worth $33.4K as of Q3 2026.
  • Allworth Financial left its MoonLake Immunotherapeutics share count unchanged in Q3 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q3 2026, its #2947 holding.
  • Allworth Financial first reported a position in MoonLake Immunotherapeutics in Q2 2025 and has held it in 6 quarters since.
  • 106 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Allworth Financial's 13F filing for Q3 2026, filed 6 Nov 2026.